Effects of Rosuvastatin on Progression of Stenosis in Adult Patients With Congenital Aortic Stenosis (PROCAS Trial)

Denise Linde, Sing Yap, APJ van Dijk, W Budts, PG Pieper, PH van der Burgh, BJM Mulder, Maarten Witsenburg, Judith Cuypers, Jan Lindemans, Hanneke Takkenberg, Jolien Hesselink

Research output: Contribution to journalArticleAcademicpeer-review

38 Citations (Scopus)


Recent trials have failed to show that statin therapy halts the progression of calcific aortic stenosis (AS). We hypothesized that statin therapy in younger patients with congenital AS would be more beneficial, because the valve is less calcified. In the present double-blind, placebo-controlled trial, 63 patients with congenital AS (age 18 to 45 years) were randomly assigned to receive either 10 mg of rosuvastatin daily (n = 30) or matched placebo (n = 33). The primary end point was the progression of peak aortic valve velocity. The secondary end points were temporal changes in the left ventricular mass, ascending aortic diameter, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The median follow-up was 2.4 years (interquartile range 1.9 to 3.0). The mean increase in peak velocity was 0.05 +/- 0.21 m/s annually in the rosuvastatin group and 0.09 +/- 0.24 m/s annually in the placebo group (p = 0.435). The annualized change in the ascending aorta diameter (0.4 +/- 1.7 mm with rosuvastatin vs 0.5 +/- 1.6 mm with placebo; p = 0.826) and left ventricular mass (1.1 +/- 15.8 g with rosuvastatin vs - 3.7 +/- 30.9 g with placebo; p = 0.476) were not significantly different between the 2 groups. Within the statin group, the NT-proBNP level was 50 pg/ml (range 19 to 98) at baseline and 21 pg/ml (interquartile range 12 to 65) at follow-up (p = 0.638). NT-proBNP increased from 40 pg/ml (interquartile range 20 to 92) to 56 pg/ml (range 26 to 130) within the placebo group (p = 0.008). In conclusion, lipid-lowering therapy with rosuvastatin 10 mg did not reduce the progression of congenital AS in asymptomatic young adult patients. Interestingly, statins halted the increase in NT-proBNP, suggesting a potential positive effect of statins on cardiac function in young patients with congenital AS. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011; 108:265-271)
Original languageUndefined/Unknown
Pages (from-to)265-271
Number of pages7
JournalAmerican Journal of Cardiology
Issue number2
Publication statusPublished - 2011

Research programs

  • EMC COEUR-09
  • EMC MM-01-25-01

Cite this